Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 18:8:e33.
doi: 10.15420/cfr.2022.01. eCollection 2022 Jan.

Ventricular Assist Devices: Challenges of the One-device Era

Gassan Moady  1   2 , Shaul Atar  1   2 , Binyamin Ben-Avraham  3   4 , Tuvia Ben-Gal  3   4
Affiliations
Review

Ventricular Assist Devices: Challenges of the One-device Era

Gassan Moady et al. Card Fail Rev. .

Abstract

Heart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device - the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare device replacement in small patients, new surgical techniques and device adaptation will be needed. The new single-device era will hopefully encourage scientists and engineers to create innovations in the advanced HF arena. Special considerations should be taken during the COVID-19 pandemic when treating patients with LVADs.

Keywords: HeartMate 3; HeartWare; left ventricular assist device; mechanical circulatory support; paediatric mechanical circulatory support.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Evolution of the One-device Era
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. McDonagh TA, Metra M, Adamo M et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726. doi: 10.1093/eurheartj/ehab670. - DOI - PubMed
    1. Birks EJ. Left ventricular assist devices. Heart. 2010;96:63–71. doi: 10.1136/hrt.2007.130740. - DOI - PubMed
    1. Ben Avraham B, Crespo-Leiro MG, Filippatos G et al. HFA of the ESC position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider part 1: introduction and at the non-hospital settings in the community. ESC Heart Fail. 2021;8:4394–408. doi: 10.1002/ehf2.13588. - DOI - PMC - PubMed
    1. Mehra MR, Uriel N, Naka Y et al. MOMENTUM 3 investigators. A fully magnetically levitated left ventricular assist device – final report. N Engl J Med. 2019;380:1618–27. doi: 10.1056/NEJMoa1900486. - DOI - PubMed
    1. Milano CA, Rogers JG, Tatooles AJ et al. HVAD: the Endurance supplemental trial. JACC Heart Fail. 2018;6:792–802. doi: 10.1016/j.jchf.2018.05.012. - DOI - PubMed